NCT04838405View on ClinicalTrials.gov

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

June 18, 2024

Study Completion Date

August 2, 2024

Conditions
Diabetes
Interventions
DRUG

CT-388

Synthetic Peptide

DRUG

Placebo

Placebo

Trial Locations (2)

6009

Carmot Clinical Research Unit 101, Perth

66260

Carmot Clinical Research Unit 105, Monterrey

Sponsors
All Listed Sponsors
collaborator

Carmot Australia First Pty Ltd

INDUSTRY

lead

Carmot Therapeutics, Inc.

INDUSTRY